NanoInnovations
NanoInnovations is an R&D-stage company developing a smart nanosensor platform with Machine Learning algorithms for non-invasive healthcare diagnostics via bio-fluid analysis, targeting COVID-19 severity prediction, diabetes, and heart failure monitoring.
- Company typePrivate
- Founded2014
- HeadquartersSugar Land, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What NanoInnovations does
NanoInnovations is a privately held, research and development-stage company founded in 2014 by Dr. Huma Jafry and headquartered in Sugar Land, Texas. The company is building a smart nanosensor platform combined with Machine Learning algorithms for healthcare analytics, focused on non-invasive analysis of bio-fluids such as sweat and saliva to generate patient-specific diagnostic and prognostic outputs. Active and planned use cases include COVID-19 severity prediction, diabetes monitoring, and heart failure detection.
The company's core offering is a single Smart Nanosensor Platform that gathers multivariate data from bio-fluids and applies AI/ML algorithms for real-time analysis. The underlying technology originated from the founder's Ph.D. and postdoctoral work in Nanomaterials Chemistry at Rice University, with early-stage development catalyzed by participation in the Wendy Schmidt Ocean Health xPrize Competition. As of December 2020, NanoInnovations is collaborating with the University of Texas Health Science in Houston on an NSF-funded project to develop AI-based algorithms for predicting COVID-19 clinical outcomes using salivary analytics.
NanoInnovations operates with 1-10 employees and has no disclosed commercial revenue. Its primary disclosed funding is a $247,239 National Science Foundation Small Business Technology Transfer (STTR) Phase I grant awarded in December 2020. The company is pre-commercial, monetizing through research grants and academic partnerships rather than direct enterprise sales, and no institutional venture capital or private equity backing is disclosed in the available sources.
NanoInnovations firmographics
Firmographics- Name
- NanoInnovations
- Legal name
- NanoInnovations
- Website
- https://nanoinnovations-health.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NanoInnovations is an R&D-stage company developing a smart nanosensor platform with Machine Learning algorithms for non-invasive healthcare diagnostics via bio-fluid analysis, targeting COVID-19 severity prediction, diabetes, and heart failure monitoring.
- Ownership category
- akta.pro rank
NanoInnovations industry classification
Industry- Product category
- Medical Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in Nanotechnology (541713)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where NanoInnovations is headquartered
LocationHeadquarters
- HQ city
- Sugar Land
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NanoInnovations business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Research Grants: The company currently operates primarily through research grants, including NSF STTR funding for COVID-19 diagnostic development. This represents early-stage funding for R&D rather than commercial revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NanoInnovations product offering
Product offeringCore offering
NanoInnovations develops a smart nanosensor platform that gathers multivariate data from bio-fluids such as sweat and saliva, which is analyzed in real-time with AI/ML algorithms to generate patient-specific diagnostic and prognostic outputs. The technology is applied to healthcare analytics use cases including diabetes monitoring, heart failure detection, and COVID-19 severity prediction. The company is currently in the research and development stage, validating its platform through partnerships with universities and healthcare providers.
Product overview
NanoInnovations offers a single unified product: the Smart Nanosensor Platform. This platform combines smart nanosensor technology with Machine Learning algorithms to collect multivariate data from bio-fluids (sweat and saliva) and generate real-time diagnostic and prognostic outputs for healthcare analytics. The platform has been applied to diabetes monitoring, heart failure detection, and COVID-19 severity prediction through AI-based algorithms.
Differentiator
Problem solved
Functional benefit
Products and services
- Smart Nanosensor Platform A versatile nanosensor-based platform that gathers multivariate data from bio-fluids such as sweat and saliva, which is analyzed in real-time with AI/ML algorithms to generate patient-specific diagnostic and prognostic outputs for healthcare applications including diabetes monitoring, heart failure detection, and infectious disease management. Targeted at hospitals, healthcare systems, and research institutions.
- AI-Based COVID-19 Severity Prediction Algorithm An AI-based algorithm that combines nanosensors with salivary analytics to predict clinical outcomes in COVID-19 patients, designed to predict illness severity at initial diagnosis and enable efficient hospital resource allocation. Targeted at hospitals and clinical research institutions.
Quantifiable outcome
- Accurate prediction of COVID-19 illness severity at initial diagnosis
Companies that use NanoInnovations
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
NanoInnovations technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
NanoInnovations partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of Texas Health Science in HoustoncoreNanoInnovations is collaborating with the University of Texas Health Science in Houston for a NSF-funded research project to develop AI-based algorithms using nanosensors and salivary analytics for predicting clinical outcomes in COVID-19 patients. This partnership enables the company to access clinical research capabilities and academic expertise for technology validation and development.
Scale indicators1 record
Recent moves3 records
Expansion highlights4 records
NanoInnovations competitors and assessment
Company assessmentBroad incumbents
- Dexcom: Market-leading CGM manufacturer with FDA-cleared continuous glucose sensors, representing the established standard NanoInnovations would need to displace for diabetes monitoring.
- Abbott (Diabetes Care / Freestyle Libre): Dominant incumbent in continuous glucose monitoring via Freestyle Libre, addressing the same diabetes-monitoring use case NanoInnovations targets with its bio-fluid nanosensors.
- Nanostring Technologies: Provides multiplexed diagnostics and life-science research tools, relevant as a broader platform vendor in advanced diagnostics with both research and clinical applications.
- Medtronic (Diabetes / Diagnostics): Major medical device incumbent offering continuous glucose monitoring and broader diagnostic products; comparable as an established competitor that NanoInnovations would need to partner with or displace.
Emerging players
- Owlstone Medical: Breath-based diagnostics platform leveraging proprietary sensor technology plus analytics for disease detection — analogous approach of using novel sensor chemistry with AI to deliver clinical outputs.
- Senseonics (Eversense): Developer of an implantable long-term continuous glucose sensor; comparable as a smaller, sensor-focused diagnostics company pursuing non-traditional bio-fluid monitoring.
- Quantum-Si: Developer of a single-molecule protein sequencing platform with embedded AI analytics; comparable as an instrument-plus-AI diagnostics company in early commercial stages.
- Cue Health: Molecular diagnostics platform with connected at-home testing (notably COVID-19), directly relevant as a comparator in AI-enabled diagnostics from non-traditional samples.
Direct peers
- Cardea Bio: Develops graphene-biosensor chips for molecular and health analytics, sharing NanoInnovations' core concept of pairing novel nano-scale biosensors with AI/ML data interpretation for diagnostics.
- Profusa: Builds injectable and wearable biosensors for continuous monitoring of bio-fluids (interstitial fluid, sweat), directly comparable to NanoInnovations' nanosensor platform for non-invasive chronic disease monitoring.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
NanoInnovations social profiles
Digital presenceNanoInnovations financial estimates
Financial estimateRevenue estimate
Valuation estimate
NanoInnovations leadership team
Management profileNumber of profiles
Profiles4 records
NanoInnovations funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NanoInnovations M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NanoInnovations
What does NanoInnovations do?
NanoInnovations develops a smart nanosensor platform that gathers multivariate data from bio-fluids such as sweat and saliva, which is analyzed in real-time with AI/ML algorithms to generate patient-specific diagnostic and prognostic outputs. The technology is applied to healthcare analytics use cases including diabetes monitoring, heart failure detection, and COVID-19 severity prediction. The company is currently in the research and development stage, validating its platform through partnerships with universities and healthcare providers.
Is NanoInnovations a public or private company?
NanoInnovations is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NanoInnovations founded?
NanoInnovations was founded in 2014. It employs 1 to 10 people.
Where is NanoInnovations based?
NanoInnovations is headquartered in Sugar Land, United States, in the North America region.
How does NanoInnovations make money?
One revenue line is on record: research Grants.
Who are NanoInnovations's main competitors?
Broad incumbents on record are Dexcom, Abbott (Diabetes Care / Freestyle Libre), Nanostring Technologies and Medtronic (Diabetes / Diagnostics). Emerging players are Owlstone Medical, Senseonics (Eversense), Quantum-Si and Cue Health. Direct peers are Cardea Bio and Profusa.
Does NanoInnovations have an API?
No public API is recorded for NanoInnovations.
What industry is NanoInnovations in?
NanoInnovations's product category is Medical Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 541714 and its SIC code is 2835.